The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical observation of Danhong Injection combined with tirofiban hydrochloride in treatment of acute coronary syndrome
Author(s): 
Pages: 1455-1459
Year: Issue:  12
Journal: World Phytomedicines

Keyword:  Danhong InjectionTirofiban Hydrochloride for injectionacute coronary syndromeLVEFLVEDDLVESD;
Abstract: Objective To observe the clinical effect of Danhong Injection combined with tirofiban hydrochloride in treatment acute coronary syndrome. Methods Patients(86 cases) with acute coronary syndrome were enrolled in this study from September 2013 to September 2015. According to the different treatment plan, patients were divided into treatment group(43 cases) and control group(43 cases). The patients in the control group were iv administered with Tirofiban Hydrochloride for injection on the basis of foundation treatment, and the starting dosage was 0.4 μg/(kg·min) in 30 min, and the maintain dosage of iv was 0.1 μg/(kg·min) for 24 h. They were administered with emergency PCI. The patients in the treatment group were po administered with Danhong Injection on the basis of control group, 40 m L Danhong Injection added into 100 m L 5% Glucose Injection, once daily. The patients in two groups were treated for 14 d. After treatment, the clinical efficacy were evaluated, and the changes of LVEF, LVEDD, and LVESD in two groups were compared. The situations of ST segment decline and bleeding in two groups were observed. The occurrences of major adverse cardiac events such as recurrence angina pectoris, new myocardial infarction, and stubborn heart deficiency in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.74% and 93.02%, respectively, and there were differences between two groups(P < 0.05). After treatment, LVEF, LVEDD, and LVESD in two groups were significantly elevated, and the difference was statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). The ST segment fell back rate in the control group was 65.12%, and that in the treatment groups was 83.72%, with significant difference between two groups(P < 0.05). The incidences of bleeding in the control and treatment group were 13.95% and 11.63%, respectively, and there was no statistically significant difference between two groups. The incidence rates of adverse cardiovascular events in two groups were 13.95% and 2.33%, respectively, with significant difference between two groups(P < 0.05). Conclusion Danhong Injection combined with tirofiban hydrochloride has clinical curative effect in treatment acute coronary syndrome, and can improve heart function, and can reduce the incidence of cardiac adverse events, which has a certain clinical application value.
Related Articles
No related articles found